Is MiMedx Group, Inc. (MDXG) a Buy, Sell, or Hold?
MiMedx Group, Inc.
NASDAQ:MDXG
$4.2 USD
$0.12 (2.94%)
- Volume
- 1.41M
- Average Volume
- 1.57M
- Market Capitalization
- $625.57M
- P/E Ratio
- 20.48
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $7.99
- Year Low
- $3.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.39
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joseph H. Capper |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MDXG |
| CUSIP | 602496101 |
| CIK | 0001376339 |
| Web | https://www.mimedx.com |
| Phone | 770 651 9100 |
| Currency | USD |
| Employees | 808 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.39 |
| Quick Ratio | 4.81 |
| Cash Ratio | 3.59 |
Sales & Book Value
| Annual Sales | $418.63M |
| Price / Sales | 1.61 |
| Cash Flow | 0.44 |
| Price / Cash Flow | 9.55 |
| Price / Book | 2.57 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -58.00% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.32 |
| Trailing P/E Ratio | 20.48 |
| PEG Ratio | -0.82 |
| P/E Growth | -0.82 |
| Net Income | $48.58M |
| Net Margin | 7.88% |
| Pretax Margin | 10.87% |
| Return on Equity | 12.86% |
| Return on Assets | 9.94% |
Financials Score
| AltmanZ Score | 7.82 |
| Piotroski Score | 6.00 |
| Working Capital | 195.78M |
| Total Assets | 308.68M |
| Ebit | 43.98M |
| Market Cap | 609.93M |
| Total Liabilities | 65.74M |
Poll Results
About MiMedx Group, Inc. (NASDAQ:MDXG) Stock
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, se ... mi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
2026-05-21 15:45:00
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
2026-05-21 08:45:00
MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.
2026-05-19 18:15:00
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-05-15 00:00:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG PR Newswire
2026-05-14 23:01:00
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-05-12 16:52:00
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is the Options Market Predicting a Spike in MiMedx Group Stock?
2026-05-11 15:40:29
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
MiMedx: The Hard Math Behind My Downgrade To Hold
2026-05-09 05:04:28
MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited.
Frequently Asked Questions
-
What is the current MiMedx Group, Inc. (MDXG) stock price?
-
MiMedx Group, Inc.(NASDAQ:MDXG) stock price is $4.2 in the last trading session. During the trading session, MDXG stock reached the peak price of $7.99 while $3.03 was the lowest point it dropped to. The percentage change in MDXG stock occurred in the recent session was 2.94% while the dollar amount for the price change in MDXG stock was $0.12.
-
MDXG's industry and sector of operation?
-
The NASDAQ listed MDXG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MDXG?
-
Kimberly Maersk-Moller | Chief Commercial Officer
Tracy Chastain | Chief Human Resources Officer
Eric A. Smith | Senior VP of Marketing & International
Joseph H. Capper | Chief Executive Officer & Director
Matthew Notarianni | Head of Investor Relations -
How many employees does MDXG have?
-
Number of MDXG employees currently stands at 808. MDXG operates from 1775 West Oak Commons Court, NE, Marietta, GA 30062, US.
-
Link for MDXG official website?
-
Official Website of MDXG is: https://www.mimedx.com
-
How do I contact MDXG?
-
MDXG could be contacted at phone #770 651 9100 and can also be accessed through its website. MDXG operates from 1775 West Oak Commons Court, NE, Marietta, GA 30062, US.
-
How many shares of MDXG are traded daily?
-
The average number of MDXG shares traded daily for last 3 months was 1.57M.
-
What is the market cap of MDXG currently?
-
The market value of MDXG currently stands at $625.57M with its latest stock price at $4.2